finanzen.net

Esperite Aktie WKN: A0YB5B / ISIN: NL0009272137

0,0593EUR
-0,0090EUR
-13,18%
08:00:39
0,0775EUR
+0,0032EUR
+4,31%
14:45:52
KAUFEN
VERKAUFEN
mehr Daten anzeigen

Esperite News

01.06.17
ESPERITE (ESP): L1 Capital subscribes to the second packed tranche today, ahead of schedule (GlobeNewswire)
31.05.17
ESPERITE (ESP) : L1 Capital confirms its investment in Esperite and announces new funding for up to EUR 1.1 million before July 12, 2017 (GlobeNewswire)
31.05.17
ESPERITE (ESP) : L1 Capital confirms its investment in Esperite and announces new funding for up to EUR 1.1 million before July 12, 2017 (GlobeNewswire)
31.05.17
ESPERITE (ESP) Q1 consolidated revenue higher compared to budget (GlobeNewswire)
31.05.17
ESPERITE (ESP) has concluded new agreements with its note holders (GlobeNewswire)
23.05.17
ESPERITE (ESP) financial results for 2016 published (GlobeNewswire)
20.05.17
Esperite further delays publication of 2016 Annual Report (GlobeNewswire)
19.05.17
Esperite (ESP) announces that Genoma SA filed appeal to the decision ruled by the Swiss Court (GlobeNewswire)
15.05.17
Esperite (ESP) - Esperite confirms the positive development of its current and future genetic activities and announces its intentions to claim 5.2 Million euro damages against Premaitha (NIPT) (GlobeNewswire)
15.05.17
Esperite (ESP) - Esperite confirms the positive development of its current and future genetic activities and announces its intentions to claim 5.2 Million euro damages against Premaitha (NIPT) (GlobeNewswire)
11.05.17
Esperite (ESP): Patent granted in China for treatment of acute and chronic inflammatory and autoimmune diseases with EVs technology (GlobeNewswire)
05.05.17
Esperite (ESP), The Cell Factory demonstrate anti-inflammatory mode of action of CF-MEV-117 extracellular vesicle drug candidate for Epilepsy (GlobeNewswire)
26.04.17
ESPERITE delays publication of 2016 Annual Report (GlobeNewswire)
25.04.17
ESPERITE N.V. (ESP) WITH CRYOSAVE CONTRIBUTES TO TREATING A 9 YEAR OLD CHILD WITH THALASSEMIA MAJOR IN SWITZERLAND (GlobeNewswire)
24.04.17
ESPERITE's shareholders approved the external financing of up to EUR 13 million (GlobeNewswire)
10.03.17
Esperite N.V. convenes Extraordinary General Meeting of Shareholders regarding external financing of up to EUR 13 million (GlobeNewswire)
08.03.17
Esperite secures external financing of up to EUR 9 million to support its commercial activity and development of innovative technologies (GlobeNewswire)
08.03.17
Esperite secures external financing of up to EUR 9 million to support its commercial activity and development of innovative technologies (GlobeNewswire)
28.02.17
Esperite N.V.: Update on Financing (GlobeNewswire)
31.12.16
Esperite N.V.: Update on Financing (GlobeNewswire)
08.11.16
Esperite N.V. : Stem Cells, Genetic Tests and Pharmaceuticals (GlobeNewswire)
20.10.16
Esperite N.V. (ESP) expands extracellular vesicles (exosomes) products portfolio to include inflammatory bowel disease. The Cell Factory develops therapy for Crohn's disease. (GlobeNewswire)
30.09.16
Esperite (ESP) leads international consortium for clinical translation of extracellular vesicles use in various therapies (GlobeNewswire)
29.08.16
Esperite N.V. (ESP) announces additional information on envisaged financing (GlobeNewswire)
23.08.16
Esperite N.V. (ESP) publishes revenue increase of 6% compared to HY1 2015 and 8% to HY2 2015; Significant EBITDA improvement from minus EUR 2.8 million in HY2 2015 to minus EUR 1.5 million HY 2016 (GlobeNewswire)

Esperite News

Esperite News: auf dieser Seite finden Sie alle Esperite News und Nachrichten zur Esperite Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Esperite News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Esperite News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.

Meistgelesene Esperite News

Keine Nachrichten gefunden.
Weitere Esperite News

Esperite Peer Group News

Keine Nachrichten gefunden.

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
SteinhoffA14XB9
Deutsche Bank AG514000
NEL ASAA0B733
Beyond MeatA2N7XQ
Daimler AG710000
Infineon AG623100
Amazon906866
TeslaA1CX3T
Lufthansa AG823212
BayerBAY001
CommerzbankCBK100
Microsoft Corp.870747
Apple Inc.865985
BASFBASF11